What podcasts say about Dan Barber
Every statement, with the speaker, the exact quote and the moment it was said.
What Dan Barber has said on podcasts
6 statements · 5 positive · 1 neutral
EQT Therapeutics reports six FDA approvals, global sales, and 2.5 billion doses delivered.
“We've actually been around for about two decades, and over those two decades, we have six approvals with the FDA. We have product that is sold in six continents. We have 2.5 billion doses we put in the hands of patients.”
Open the episode · Mad Money w/ Jim Cramer 9/25/25Listen at 29:18
EQT’s oral anaphylaxis product could reach $1 billion worldwide at peak sales.
“with our new product, our antifilm product, we finally have a potential blockbuster product on our hands. It's under review with the FDA right now. And when I say blockbuster, in my mind, I think it could be a billion dollars worldwide at peak.”
Open the episode · Mad Money w/ Jim Cramer 9/25/25Listen at 29:39
Anafilm is the first and only oral rescue medication for anaphylaxis.
“we have the first and only oral rescue medication for the treatment of anaphylaxis.”
Open the episode · Mad Money w/ Jim Cramer 9/25/25Listen at 29:58
The FDA is scheduled to decide on Anafilm by January 31.
“The action dates when the FDA will give you an answer of January 31st.”
Open the episode · Mad Money w/ Jim Cramer 9/25/25Listen at 32:53
EQT expects annual rescue-product prescriptions to rise from five to ten million.
“with a better product, and with the natural growth rate in the market, we think going from 5 to 10 million is very doable in the next few years.”
Open the episode · Mad Money w/ Jim Cramer 9/25/25Listen at 33:48
EQT plans alopecia areata as its next adrenaline-platform product.
“Alopecia areata will be our next one, so different release profile, and we'll have more products after that.”
Open the episode · Mad Money w/ Jim Cramer 9/25/25Listen at 34:37
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.